Abraxane: Ph II tnAcity data

Top-line data from 191 women with metastatic TNBC who received no prior systemic chemotherapy in the Phase II portion of the double-blind, international Phase II/III tnAcity trial showed that first-line treatment with once-weekly 125 mg/m² Abraxane on days 1 and 8 of each 21-day cycle plus carboplatin significantly improved PFS vs. Abraxane plus gemcitabine (7.4 vs. 5.4 months, HR=0.6, 95% CI: 0.39, 0.93, p=0.02) and vs. carboplatin plus gemcitabine (7.4 vs. 6 months, HR=0.61, 95% CI: 0.39, 0.94, p=0.03). Data were presented at the San Antonio Breast Cancer Symposium. Celgene said it that after considering the "rapidly changing breast cancer treatment landscape," the company will not move forward with the trial’s Phase III portion and will instead focus its breast cancer research support on combinations of Abraxane and immunotherapies...